IBTA e-News December 2019 now out

By 7th January 2020 January 31st, 2020 News archive
[31 December 2019] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News December 2019 edition in full online here.

Some of the highlights from this month's round-up:

  • The EANO EURACAN medulloblastoma guidelines have been published online in the Lancet Oncology. EANO and EURACAN guidelines provides recommendations for the diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.
  • In a study published in Nature Scientific Report, researchers have documented a new technique for delivering controlled levels of chemotherapy agents directly to brain tumours via a multi-layered chemotherapy-releasing implant. They constructed chemotherapy-loaded tablet-like discs that harnessed the unique properties of each material so as to deliver a sustained dose of chemotherapy when implanted into a brain tumour site.
  • Enrolment is open for the STELLAR trial, which is evaluating the targeted therapy eflornithine oral solution in recurrent anaplastic astrocytoma.
  • According to a study published in Cancer Communications, bortezomib, a drug approved for the treatment of multiple myeloma, appears to sensitise glioma tumours to the cancer-killing effects of temozolomide.
  • A paper published in Nature Genetics has identified that several types of highly aggressive and poor prognosis paediatric brain tumours have their roots during early brain development.  Paper co-author Professor Nada Jabado is quoted in a news report saying: “The challenge is now to identify how best to unlock these cells promoting their differentiation, and allowing for normal processes to take over.”
  • Results of a two-part, phase I/IIa, open-label study of the drug dabrafenib (Tafinlar) have shown anti-tumour activity in paediatric patients with recurrent or refractory BRAF V600 mutation, according to the findings. These results have been published in Clinical Cancer Research.
  • Diffusion Pharmaceuticals has presented phase 3 clinical trial data at the inaugural Glioblastoma Drug Development Summit in Boston, USA, showing that an optimized dosing regimen of the agent trans sodium crocetinate plus standard of care increases survival in newly diagnosed inoperable glioblastoma patients.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.